ALNY:NGS-Alnylam Pharmaceuticals Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 274.91

Change

0.00 (0.00)%

Market Cap

USD 3.92B

Volume

0.46M

Analyst Target

USD 166.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 121.60B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 92.70B
ARGX argenx NV ADR

N/A

USD 35.89B
BGNE BeiGene Ltd

N/A

USD 22.85B
MRNA Moderna Inc

N/A

USD 21.00B
UTHR United Therapeutics Corporatio..

N/A

USD 16.70B
RPRX Royalty Pharma Plc

N/A

USD 15.14B
INCY Incyte Corporation

N/A

USD 14.67B
SMMT Summit Therapeutics PLC

N/A

USD 13.75B
PCVX Vaxcyte Inc

N/A

USD 13.28B

ETFs Containing ALNY

GNOG:LSE Global X Genomics & Biote.. 6.94 % 0.00 %

N/A

USD 8.22M
GN0M:XETRA Global X Genomics & Biote.. 6.79 % 0.00 %

N/A

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 6.79 % 0.00 %

N/A

USD 8.00M
MSGR 6.64 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 5.76 % 0.00 %

N/A

N/A
CURG:LSE VanEck Genomics and Healt.. 5.05 % 0.00 %

N/A

USD 4.80M
BIOT:SW L&G Pharma Breakthrough U.. 3.89 % 0.00 %

N/A

N/A
BBH VanEck Biotech ETF 3.47 % 0.35 %

N/A

USD 0.43B
BTEC:SW iShares Nasdaq US Biotech.. 3.20 % 0.00 %

N/A

N/A
CURE:AU ETFS S&P Biotech ETF 2.62 % 0.00 %

N/A

USD 0.04B
BBP Virtus LifeSci Biotech Pr.. 2.39 % 0.79 %

N/A

USD 0.02B
BIB ProShares Ultra Nasdaq Bi.. 2.39 % 0.95 %

N/A

USD 0.07B
EQQJ:XETRA Invesco NASDAQ Next Gener.. 2.29 % 0.00 %

N/A

USD 0.05B
EQJS:LSE Invesco NASDAQ Next Gener.. 2.18 % 0.00 %

N/A

USD 0.05B
JNDQ:AU BETAJNDQ ETF UNITS 2.14 % 0.00 %

N/A

N/A
EQQJ:SW Invesco NASDAQ Next Gener.. 2.11 % 0.00 %

N/A

N/A
EQQJ:LSE Invesco NASDAQ Next Gener.. 2.02 % 0.00 %

N/A

N/A
TMFX Motley Fool Next Index ET.. 1.97 % 0.00 %

N/A

USD 0.03B
LABU Direxion Daily S&P Biotec.. 1.48 % 1.14 %

N/A

USD 0.99B
WELP:LSE HAN-GINS Indxx Healthcare.. 1.36 % 0.00 %

N/A

N/A
THNZ:XETRA L&G Global Thematic ESG E.. 0.87 % 0.00 %

N/A

N/A
IUSZ:SW iShares Edge MSCI USA Siz.. 0.52 % 0.00 %

N/A

N/A
IWSZ:SW iShares Edge MSCI World S.. 0.21 % 0.00 %

N/A

USD 0.29B
ETHO Amplify ETF Trust 0.00 % 0.45 %

N/A

USD 0.18B
FFTY Innovator IBD® 50 ETF 0.00 % 0.80 %

N/A

N/A
FHH:CA First Trust AlphaDEX US H.. 0.00 % 0.77 %

N/A

CAD 0.01B
FXH First Trust Health Care A.. 0.00 % 0.63 %

N/A

USD 1.19B
IBB iShares Biotechnology ETF 0.00 % 0.47 %

N/A

USD 6.55B
LABS 0.00 % 0.45 %

N/A

N/A
QRH:CA 0.00 % 1.20 %

N/A

N/A
RBUS 0.00 % 0.30 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

N/A

N/A
IUSF:LSE iShares IV Public Limited.. 0.00 % 0.00 %

N/A

USD 0.29B
IUSZ:LSE iShares Edge MSCI USA Siz.. 0.00 % 0.00 %

N/A

USD 0.29B
IWFS:LSE iShares MSCI World Size F.. 0.00 % 0.00 %

N/A

USD 0.28B
IWSZ:LSE iShares IV Public Limited.. 0.00 % 0.00 %

N/A

USD 0.28B
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

N/A

N/A
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
ETLI:XETRA L&G Pharma Breakthrough U.. 0.00 % 0.00 %

N/A

USD 0.02B
IS3T:XETRA iShares MSCI World Size F.. 0.00 % 0.00 %

N/A

USD 0.24B
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
GERM 0.00 % 0.00 %

N/A

N/A
BMED BlackRock Future Health E.. 0.00 % 0.00 %

N/A

USD 4.07M
QQQJ Invesco NASDAQ Next Gen 1.. 0.00 % 0.00 %

N/A

USD 0.63B
QQQN VictoryShares Nasdaq Next.. 0.00 % 0.00 %

N/A

USD 0.02B
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.00 %

N/A

CAD 0.01B
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

N/A

USD 0.04B
XGES:LSE Xtrackers MSCI Genomic He.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 43.62% 55% F 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 43.62% 55% F 76% C+
Trailing 12 Months  
Capital Gain 55.23% 52% F 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 55.23% 52% F 75% C
Trailing 5 Years  
Capital Gain 268.96% 70% C- 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 268.96% 70% C- 86% B+
Average Annual (5 Year Horizon)  
Capital Gain 14.14% N/A N/A 72% C
Dividend Return 14.14% N/A N/A 70% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 27.17% N/A N/A 66% D+
Risk Adjusted Return 52.03% N/A N/A 80% B-
Market Capitalization 3.92B 100% F 97% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 142.92 1% 1%
Price / Cash Flow Ratio 338.85 1% 1%
Price/Free Cash Flow Ratio 203.76 1% 2%
Management Effectiveness  
Return on Equity -1,500.66% 4% 2%
Return on Invested Capital -34.83% 70% 26%
Return on Assets 1.73% 96% 72%
Debt to Equity Ratio -462.63% 98% 98%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.